Sanofi–GSK COVID-19 vaccine

Sanofi–GSK COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Other names	VAT00002
Routes of; administration	Intramuscular

Sanofi–GSK COVID-19 vaccine also known as VAT00002 is a COVID-19 vaccine candidate developed by Sanofi Pasteur and GSK.^[1]^[2]^[3]

Development

VAT00002 is under development by the French pharmaceutical and the British pharmaceutical company GlaxoSmithKline.^[4] Advanced clinical trials of the vaccine were delayed in December 2020 after it failed to produce a strong immune response in people over the age of 50, most likely due to an insufficient antigen concentration in the vaccine, delaying the launch of the vaccine to late 2021.^[5]

Clinical trials

As of August 2020, COVID-19 vaccine development in Sanofi underscores its fundamental competitiveness weakness, that management has been struggling and failed to deal with for past many years beyond cutting more cost. Unfortunately, even though Sanofi-GSK approach is based on pre-existing, approved platform and technology (as with Flublok flu) without reinventing the wheel of the necessary infrastructure,^[6] the company lags behind many other rivals in delivering a working vaccine. Sanofi plans to start Phase 1 clinical testing only in September and expects emergency use approval in first half 2021.^[7] Competitors such as Novavax already completed Phase 1 with promising results^[8] and Moderna-NIH already initiated its Phase 3 trial.^[9]

Deployment

In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi. It uses a recombinant protein-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021.^[10] The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.^[11]

According to CNBC reports,^[12] as part of the 2.1 billion US government deal, more than 750 million goes to supporting Sanofi-GSK in vaccine development and clinical trials.

References

^ "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older". clinicaltrials.gov. United States National Library of Medicine. Retrieved 11 March 2021.{{cite web}}: CS1 maint: url-status (link)
^ "Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 11 March 2021.{{cite web}}: CS1 maint: url-status (link)
^ "Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older". pactr.samrc.ac.za. Pan African Clinical Trials Registry. Retrieved 24 March 2021.{{cite web}}: CS1 maint: url-status (link)
^ https://www.bbc.com/news/business-54009633
^ Taylor, Nick Paul (11 December 2020). "Weak clinical data force Sanofi, GSK to delay COVID-19 vaccine". Fierce Biotech. Retrieved 25 January 2021.
^ Sanofi and GSK land $2.1 billion deal with U.S. for Covid-19 vaccine development and 100 million doses, 31 July 2020, retrieved 7 August 2020
^ Sanofi accelerates coronavirus vaccine plans, 24 June 2020, retrieved 7 August 2020
^ Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate, 4 August 2020, retrieved 7 August 2020
^ Phase 3 clinical trial of investigational vaccine for COVID-19 begins, 27 July 2020, retrieved 7 August 2020
^ "Coronavirus vaccine: UK signs deal with GSK and Sanofi". 29 July 2020 – via www.bbc.com.
^ "U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine". CNBC.
^ U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine, 31 July 2020, retrieved 7 August 2020

External links

Scholia has a profile for Sanofi–GSK COVID-19 vaccine (Q106265257).

[1] "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older". clinicaltrials.gov. United States National Library of Medicine. Retrieved 11 March 2021.{{cite web}}: CS1 maint: url-status (link)

[2] "Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 11 March 2021.{{cite web}}: CS1 maint: url-status (link)

[3] "Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older". pactr.samrc.ac.za. Pan African Clinical Trials Registry. Retrieved 24 March 2021.{{cite web}}: CS1 maint: url-status (link)

[4] ttps://www.bbc.com/news/business-54009633

[5] Taylor, Nick Paul (11 December 2020). "Weak clinical data force Sanofi, GSK to delay COVID-19 vaccine". Fierce Biotech. Retrieved 25 January 2021.

[6] Sanofi and GSK land $2.1 billion deal with U.S. for Covid-19 vaccine development and 100 million doses, 31 July 2020, retrieved 7 August 2020

[7] Sanofi accelerates coronavirus vaccine plans, 24 June 2020, retrieved 7 August 2020

[8] Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate, 4 August 2020, retrieved 7 August 2020

[9] Phase 3 clinical trial of investigational vaccine for COVID-19 begins, 27 July 2020, retrieved 7 August 2020

[10] "Coronavirus vaccine: UK signs deal with GSK and Sanofi". 29 July 2020 – via www.bbc.com.

[11] "U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine". CNBC.

[12] U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine, 31 July 2020, retrieved 7 August 2020

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]